期刊
FEBS JOURNAL
卷 289, 期 4, 页码 901-921出版社
WILEY
DOI: 10.1111/febs.15790
关键词
AMPK; CB1R; diabetes; mTORC1; obesity; SGLT2
资金
- Israel Science Foundation [398/20, 158/18]
- Israel Science Foundation-JFRFI [2982/20]
- ERC-2015-StG [676841]
- European Research Council (ERC) [676841] Funding Source: European Research Council (ERC)
Diabetes kidney disease is a major healthcare problem that leads to end-stage kidney disease and high mortality. Recent studies suggest that kidney proximal tubule cells play a central role in the pathophysiology of this disease by being exposed to nutrient overload, which can lead to tubular injury, inflammation, and fibrosis. Pharmacological treatments that modulate nutrient sensing and signaling in these cells have shown to have protective effects on the kidney.
Diabetes kidney disease (DKD) is a major healthcare problem associated with increased risk for developing end-stage kidney disease and high mortality. It is widely accepted that DKD is primarily a glomerular disease. Recent findings however suggest that kidney proximal tubule cells (KPTCs) may play a central role in the pathophysiology of DKD. In diabetes and obesity, KPTCs are exposed to nutrient overload, including glucose, free-fatty acids and amino acids, which dysregulate nutrient and energy sensing by mechanistic target of rapamycin complex 1 and AMP-activated protein kinase, with subsequent induction of tubular injury, inflammation, and fibrosis. Pharmacological treatments that modulate nutrient sensing and signaling in KPTCs, including cannabinoid-1 receptor antagonists and sodium glucose transporter 2 inhibitors, exert robust kidney protective effects. Shedding light on how nutrients are sensed and metabolized in KPTCs and in other kidney domains, and on their effects on signal transduction pathways that mediate kidney injury, is important for understanding the pathophysiology of DKD and for the development of novel therapeutic approaches in DKD and probably also in other forms of kidney disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据